In a significant move to address the growing demand for advanced respiratory solutions, NASDAQ-listed AGAPE ATP Corporation (ATPC) has announced a strategic collaboration with FORMEDIC Technologies Sdn. Bhd. to launch LEGA, an innovative electronic chest percussion device. This partnership aims to revolutionize respiratory care by providing critical support for patients with chronic obstructive pulmonary diseases (COPD), pneumonia, bronchiectasis, and other lung-related conditions. LEGA is designed to assist in airway clearance and secretion management, offering much-needed relief to patients in both hospital and home care settings.
A Strategic Collaboration for Advanced Respiratory Solutions
The collaboration between ATPC and FORMEDIC Technologies marks a significant advancement in the field of respiratory health. By combining their expertise, the two companies aim to address the increasing prevalence of respiratory diseases globally. LEGA, the flagship product of this partnership, has already gained traction in the medical field, with nearly 2,000 units in use across major hospitals and rehabilitation centers in Malaysia and beyond. This device is set to play a crucial role in managing respiratory conditions, providing effective airway clearance and secretion management.
The global respiratory care market is projected to grow significantly, with estimates suggesting it will reach USD 49.84 billion by 2031. This collaboration positions ATPC to capitalize on this growth, diversifying its wellness portfolio with a proven medical device. The partnership also aligns with ATPC’s long-term vision of building a holistic wellness ecosystem that encompasses both preventive and curative solutions.
Prof. Dato’ Sri Dr. How Kok Choong, the Founder and Global Group CEO of ATPC, emphasized the importance of this collaboration in addressing a critical global health need. He highlighted that the partnership allows ATPC to leverage FORMEDIC’s expertise in healthcare technology, enhancing their ability to deliver innovative solutions to patients worldwide.
LEGA: A Revolutionary Device for Respiratory Care
LEGA is an electronic chest percussion device designed to assist patients with various respiratory conditions. It helps manage secretion drainage and airway clearance, providing relief to both adults and children facing respiratory difficulties. The device is particularly beneficial for patients with chronic obstructive pulmonary diseases (COPD), pneumonia, bronchiectasis, and other lung-related conditions.
The development of LEGA involved years of research and clinical trials, ensuring its effectiveness and safety. The device has already been implemented in major healthcare facilities, demonstrating its potential to improve patient outcomes. By facilitating airway clearance and managing secretions, LEGA offers a non-invasive solution that can be used in both hospital and home care settings.
Ng Zim Guan, Director of FORMEDIC Technologies, expressed his enthusiasm for the partnership with ATPC. He noted that the collaboration would enhance the reach and impact of LEGA, allowing more patients to benefit from this innovative device. The partnership also underscores the commitment of both companies to advancing respiratory care through ongoing research and development.
Expanding Market Reach and Enhancing Patient Care
The strategic collaboration between ATPC and FORMEDIC Technologies is set to expand the market reach of LEGA, making it accessible to a broader patient population. As respiratory diseases continue to rise globally, the demand for advanced respiratory solutions is expected to grow. This partnership positions ATPC to meet this demand, providing a proven medical device that can significantly improve patient care.
The respiratory care market is estimated to be worth USD 25.95 billion in 2024, with a strong growth trajectory projected to reach USD 49.84 billion by 2031. This growth is driven by the increasing prevalence of respiratory diseases and the need for effective management solutions. By introducing LEGA to the global market, ATPC and FORMEDIC Technologies are poised to make a substantial impact on respiratory health.
Prof. Dato’ Sri Dr. How Kok Choong highlighted the strategic importance of this collaboration in diversifying ATPC’s wellness portfolio. He emphasized that the partnership aligns with ATPC’s vision of building a comprehensive wellness ecosystem, encompassing both preventive and curative solutions. The collaboration also enhances ATPC’s growth and market reach, ultimately benefiting shareholders and patients alike.
